Methods. A university hospital database was used to identify all participants treated with primary diagnosis of OVCF between 1993 and 2006. Chart review and imaging studies were used to confirm demographics, comorbidities, diagnosis, and treatment. Survival time was determined Bucladesine Others inhibitor using hospital data, national death indices and patient follow-up. Exact Fisher tests, Mann-Whitney tests, and proportional hazards regression models with Kaplan-Meier plots compared patients treated with cement augmentation with controls treated with inpatient pain management and bracing. Patients with high-energy trauma, tumors or age more than 60 years were excluded.

Results.

Within the past 12 years, 46 patients treated with cement augmentation and 129 matched controls met inclusion criteria. They did not differ with

respect to age, sex, and comorbidities. A significant survival advantage was found after cement augmentation compared with controls (P < 0.001; log rank), regardless of comorbidities, age, or the number of fractures diagnosed at the start date (P = 0.565). Controlling simultaneously for covariates, the estimated BVD-523 in vivo hazard ratio associated with cementation was 0.10 (95% confidence interval [CI] = 0.02-0.43; P = 0.002) for year 1, 0.15 (95% CI = 0.02-1.12; P = 0.064) for year 2, and 0.95 (95% CI = 0.32-2.79; P = 0.919) for subsequent follow-up.

The number of OVCFs at the start time of treatment did not affect survival benefit of cementation (P = 0.44).

Conclusion. Cement augmentation of refractory OVCF improves survival for up to 2 years when compared with conservative pain management with bed rest, narcotics, and extension bracing, regardless of age, sex, and number of fractures or comorbidities. Therefore, aggressive management should be considered for refractory OVCFs with intractable back pain.”
“Chronic daily headache (CDH) is a fairly common but disabling disorder that disproportionately affects women and afflicts individuals across all stages of adulthood. It is a dynamic disorder, marked by relatively high rates of remission and incidence. To some extent, this may be due to the accepted, but not empirically supported, cut-point of 15 headache days per month. LY2835219 in vitro The purpose of this article is to understand the CDH classification; determine the prevalence and associated demographic profile of CDH as derived from population-based studies; outline identified risk factors for development or persistence of CDH; and understand which risk factors may be more amenable to intervention. Understanding the factors that put people at risk for developing CDH helps to inform possible clinical interventions and also determines which individuals may be most in need of preventive efforts.